Vaccine of 200 crores a big success, Corona came under control due to vaccine: Expert

India has so far vaccinated 200 crore people above the age of 12 (200 Crore Vaccination) have put. Ever since India launched its vaccination campaign (Vacancy Campaign) Since then, it has taken the country more than 18 months to reach this benchmark. On January 16 last year, a nationwide vaccination campaign was launched, in the first phase of which the health workers were vaccinated. Vaccination began for frontline workers from February 2 last year and for all people above the age of 45 from April 1. India started giving a precautionary dose of Kovid-19 vaccines to all people above the age of 18 on April 10 did.

To commemorate the country’s journey so far in the fight against the Corona pandemic, National Institute of Immunology scientist Dr Vinita Bal spoke with Tv9 on the negligence and the challenges of reaching this point. .

What were the challenges in vaccinating such a large population? how did we do?

There were many challenges. A big issue was how to make the vaccine available to such a large population, how to prioritize it? We managed this successfully. Second, the safety of vaccines especially if we look at the vaccination of children. This is because in the initial phase clinical trials were conducted only on the adult population. We didn’t have enough data available, but slowly and steadily things are getting better. Third, there was hesitation among people about the vaccine. Our country is a democratic country, so obviously there was no coercion. Despite this, the response of the people to the vaccination campaign was not bad. We have succeeded in vaccinating almost 90 per cent of the people who are above 60 years of age. But then there was a decline when it was time for the second shot. A major reason for this could be that there was a lack of such a message among the people that would convince the public that both the doses were necessary for them.

There were also technical challenges with this. Since everything was happening through the CoWin App, not many people knew how to register on it. This made it difficult for many people to take shots.

There are also no nasal or transmission-blocking vaccines in the country. Nasal vaccines could have been effective in preventing infection, but making them is extremely difficult and it is not surprising that this has not happened in India yet.

Have we built any ground for indigenous studies on vaccination?

Yes, there have been many indigenous studies and we have made satisfactory progress in this matter to a great extent. There have been clinical trials on Covishiled, some of them in India. All the trials of Covaxin took place in the country. The trials of Corbeaux took place in India and the same is true for ZyCoV-D. Eventually, these will be published, some of which have already appeared in newspapers and magazines. Clinical trial data is useful for developing public health policy. Data is scattered, as CNC has examined the results of vaccine mixology to find out which one is more effective after two shots of Covishield and Covaxin. Do we need a different vaccine or a similar vaccine? We will also get answers to these questions. Recently, the mRNA Kovid-19 vaccine of Genova Biopharmaceuticals of Pune has been approved, which is going to prove to be a game changer.

What will be the status of COVID-19 vaccination in 2030?

It depends on the virus. If we don’t wear masks in crowded places, we are going to help the spread of the virus. But if we continue to follow the COVID-19 protocol, then the country will surely reach the endemic stage. Since the majority of the population will be vaccinated, major crises cannot arise in the future. But its nature is to make mutations and change the form of the virus. If there is a major change, as we have seen changes in the flu virus, it has to be found out how much our current vaccination will protect us. So far no such indications have been found with SARS-CoV-2.

Did we delay in bringing the vaccine in the fight against the corona pandemic?

Yes, we could have done better. As a country, we neither have good infrastructure nor do we have the best human resources. We also do not believe in investing in the healthcare sector and this approach needs to be changed. There is a serious lack of public health infrastructure. Our work depends on the ASHA workers and puts more burden on them. This is extremely improbable. Even if we had a lot of vaccines on the first day, we would not have been able to distribute more than what we did.

What are the two lessons this pandemic has taught us about vaccination?

It has taught us that we need to invest in science. This is a very subtle thing. If we weren’t already working on developing mRNA vaccines in certain places around the world, we wouldn’t have got them in time. We didn’t have a single mRNA vaccine until this pandemic struck us. We should invest in science without seeing immediate benefits. We should help the institutions so that they can continue their research. Sadly, India’s funding in this regard has been disappointing. If we do not invest in the science behind these vaccines, then how can India become self-reliant and a major center for manufacturing all vaccines.

We need to strengthen and sustain the public healthcare sector. We have allowed private enterprises to handle healthcare. We have only contract employment at the primary healthcare level. We must maintain well trained manpower in the government healthcare sector.

Get more health related articles click here

Similar Posts